Jefferies Maintains Johnson & Johnson to Hold with Price Target $113.00

Brokerage firm Jefferies Maintains its rating on Johnson & Johnson(NYSE:JNJ). In a research note issued to the investors, the brokerage major Raises the price-target to $113.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Jul 14, 2016.

In a different note, On Jun 14, 2016, Jefferies said it Maintains its rating on Johnson & Johnson. In the research note, the firm Raises the price-target to $108.00 per share. The shares have been rated ‘Hold’ by the firm. Standpoint Research said it Initiates Coverage on Johnson & Johnson, according to a research note issued on May 20, 2016. The shares have been rated ‘Sell’ by the firm. On May 12, 2016, BTIG Research said it Downgrades its rating on Johnson & Johnson. The shares have been rated ‘Neutral’ by the firm. On Apr 20, 2016, Goldman Sachs said it Maintains its rating on Johnson & Johnson. In the research note, the firm Raises the price-target to $112.00 per share. The shares have been rated ‘Neutral’ by the firm. On Apr 20, 2016, Barclays said it Maintains its rating on Johnson & Johnson. In the research note, the firm Raises the price-target to $115.00 per share. The shares have been rated ‘Overweight’ by the firm. On Apr 20, 2016, Argus Research said it Maintains its rating on Johnson & Johnson. In the research note, the firm Raises the price-target to $116.00 per share. The shares have been rated ‘Buy’ by the firm.

Johnson & Johnson (JNJ) made into the market gainers list on Mondays trading session with the shares advancing 0.11% or 0.14 points. Due to strong positive momentum, the stock ended at $123.14, which is also near the day’s high of $123.22. The stock began the session at $123 and the volume stood at 65,99,199 shares. The 52-week high of the shares is $124.3 and the 52 week low is $81.79. The company has a current market capitalization of $338,714 M and it has 2,75,06,44,300 shares in outstanding.

Johnson & Johnson(JNJ) last announced its earnings results on Apr 19, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $17.48B. Analysts had an estimated revenue of $17.47B. Earnings per share were $1.68. Analysts had estimated an EPS of $1.65.

Several Insider Transactions has been reported to the SEC. On Jun 9, 2016, Gary J Pruden (Exec VP, WW Chair, Med Devices) sold 9,735 shares at $116.03 per share price.Also, On Jun 9, 2016, Ronald A Kapusta (Controller, CAO) sold 3,000 shares at $115.79 per share price.On Feb 4, 2016, Peter Fasolo (VP, Global Human Resources) sold 151,385 shares at $104.11 per share price, according to the Form-4 filing with the securities and exchange commission.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *